An FDA untitled letter, a word change and the quiet lesson for GLP-1 advertising

What an FDA untitled letter is, and what the Wegovy ad earned#

Every fox learns to read a hedgerow for what has passed through it, not only what is standing in it. Regulators read advertising the same way. On 5 February 2026 the FDA's Office of Prescription Drug Promotion sent Novo Nordisk an FDA untitled letter about a television spot for the Wegovy pill that had aired in January, as Medical Daily reports. An untitled letter is milder than a warning letter, but it is a written objection, and it asks for a reply.

The agency's own letter to Novo asks for a written response within 15 working days. According to Medical Daily, the FDA said the phrases “live lighter” and “a way forward” misleadingly implied greater weight loss than other approved GLP-1 drugs, and that it knew of no data to support that. It also objected to what the spot suggested beyond weight loss: benefits such as emotional relief, reduced psychological burden, hope and direction, which the letter says the ad implied without support.

Three weeks later came a second FDA untitled letter, this time about an Ozempic video built on the line “There's Only One Ozempic”. The second letter says the comedic device communicates to viewers that competitor GLP-1 products lack meaningful benefits. Humour, in other words, is not an exemption. If a joke implies a comparison, the comparison needs evidence.

Both letters sit inside a wider push. In September 2025 the FDA said it was sending thousands of letters warning pharmaceutical companies to remove misleading ads and about 100 cease-and-desist letters to companies with deceptive ads, in its crackdown announcement. The direction of travel is not subtle, and the FDA untitled letter is the quiet middle rung of the ladder. Treat it as a scent on the wind: it tells you where the agency is prowling.

That last row deserves a pause, because it is where telehealth teams live. The trade press reported that the FDA sent warning letters to about 30 telehealth firms over misleading compounded GLP-1 marketing, including advertising drug products under the telehealth firm's own name without clarifying that the firm is not the actual compounder, per Pharmaceutical Commerce. The advertiser, not the manufacturer, is the one holding the pen.

From patients to customers: why the words matter#

Now to the news hook, the first sign of life since the FDA untitled letter landed. STAT reported, and Medical Daily summarised, that Novo increasingly describes the people who take Wegovy as customers rather than patients and now labels the drug on its website as a weight loss treatment instead of an anti-obesity or weight management medicine. The shift arrives nearly eight months after the FDA told Novo a US television ad for the Wegovy pill was false or misleading.

Mind the inference, though. Medical Daily is explicit that describing buyers as customers is not, on its own, a violation of any rule, that the FDA's authority covers US promotion while STAT described slogans used around the world, and that the agency's public index shows no further letter to Novo tied to the customers framing. This is a scent to follow after an FDA untitled letter, not a violation to allege.

Why does it matter to GLP-1 marketing? Because the channel has changed. Medical Daily reported earlier that self-pay channels make up about half of Wegovy business and 90% of demand for the pill, so with no insurer reviewing the purchase, advertising and a short telehealth visit carry more of the decision. Novo's own NovoCare page lists monthly prices by dose, $149, $199 and $299, and still says patients pay.

Language research offers a useful counterweight. A 2022 positioning analysis of online healthcare service advertisements found the ads carried multiple indicators of healthcare consumerism even while avoiding the terms consumer, customer and client. The lesson is that words and images do their work whether or not the label changes.

GLP-1 advertising for telehealth: the ground beneath the ads#

For telehealth brands the undergrowth is thicker than it looks: four rulebooks tangle in one thicket. Start with the regulation that the FDA's promotional reviewers apply. Under 21 CFR 202.1, an advertisement is misleading if it suggests, without approval, that a drug is better, more effective or useful in a broader range of conditions or patients. Every phrase you write about a prescription drug is read against that sentence, which is exactly how an FDA untitled letter is written.

Then the compounding line. In February 2026 the FDA said that in promotional materials companies cannot claim non-approved compounded products are generic versions or the same as approved drugs, in its statement on non-approved GLP-1 drugs. Novo's own 9 February statement said injectable semaglutide compounded by pharmacies was found to contain impurities of up to 86%, which shows how contested this ground has become.

Substantiation is the third leg. The FTC's health products compliance guidance says that, as a general matter, substantiation of health-related benefits needs randomised, controlled human clinical testing to meet the competent and reliable scientific standard. A testimonial, a transformation story or an emotive promise is a claim, and the FTC will ask what proves it. That unproven claim is the quarry every regulator hunts.

Paid channels add a fourth filter. Google restricts the promotion of services related to the online prescribing, dispensing and sale of prescription drugs, under its healthcare and medicines policy, which is why so many telehealth acquisition plans lean on organic, partnerships and compliant landing pages. Our own read of that landscape lives in telehealth advertising after the Hims and Hers complaint, and in our healthcare marketing work.

The UK version: no prescription drug ads at all#

Marketers working across the Atlantic meet a different den of rules. In the UK, prescription-only medicines cannot be advertised to the public, under rule 12.12 of the ASA's guidance on weight control and prescription-only medicines, and the underlying law says a person may not publish an advertisement likely to lead to the use of a prescription-only medicine, per regulation 284 of the Human Medicines Regulations 2012.

The regulator is not merely quoting the rule. In April 2026 the ASA reported that it identified around 900 ads likely to breach the rules, from 38 of the 44 advertisers monitored, in its research and enforcement report on weight-loss medicines. That is 86% of the advertisers watched, a rate high enough to say the problem is systemic rather than rogue.

For a UK or EU brand the implication is a different marketing strategy, not a quieter version of the American one. Advertise the service, the clinician, the process and the support, never the product, and keep product talk to the consultation. It is slower and less glamorous, it sidesteps the FDA untitled letter problem entirely, and it is the only route that survives contact with the ASA.

A GLP-1 marketing strategy that survives a letter#

So what would a durable GLP-1 marketing strategy look like after an FDA untitled letter? Not a rulebook so much as a set of habits, the kind a fox keeps when the ground is uneven: walk the same trail, check each step, leave nothing you cannot explain. Here is our reading, offered as practice rather than legal advice, and worth putting past your regulatory counsel.

That is the heart of GLP-1 advertising discipline: describe what happens, not what it feels like. Feeling is what the untitled letters punished. Where growth teams often go wrong is treating compliance as a final sign-off rather than a creative brief. Invite compliance to the first concept meeting and the sign-off shrinks to a signature.

If you run paid programmes, the same logic applies to paid search and paid social, where ad copy is short and the impression is everything. If content is your lane, content marketing built on evidenced, checkable claims is the safer engine. And for the corporate side of the same story, see how Novo's corporate rebrand strategy was tested in public.

The last lesson is a quiet one. A word change is not a violation and an FDA untitled letter is not a verdict. But the pattern of the last twelve months is clear enough to plan around: evidence before emotion, the label before the logo, and a second reader before launch, so the first FDA untitled letter never has to arrive.

Frequently asked questions#